摘要
目的:探讨糖化白蛋白(GA)、超敏C反应蛋白(hsCRP)以及脂蛋白(a)[LP(a)]等生化指标在2型糖尿病合并冠心病预测中的作用。方法:选择2型糖尿病合并冠心病患者共69例(A组),单纯2型糖尿病患者共67例(B组)以及健康对照组共77例(C组)。分别检测其血清或血浆GA、hsCRP、糖化血红蛋白、LP(a)等生化指标。经受试者工作特征曲线(ROC曲线)分析获得区分A组与B组的最适界值点(cutoff值)。结果:A组与B组、C组间GA、hsCRP、LP(a)值的差异均具有统计学意义。GA ROC曲线下面积0.607,在最适cutoff值为18.89%时,敏感性为73.9%,特异性为55.2%。hsCRP ROC曲线下面积为0.746,在最适cutoff值为5.09mg/L时敏感性和特异性分别为50.7%和80.1%。LP(a)ROC曲线下面积0.630,在最适cutoff值为40mg/L时,敏感性为87.0%,特异性为40.3%。结论:2型糖尿病合并冠心病患者的GA、hsCRP、LP(a)水平明显升高,GA是2型糖尿病是否合并冠心病预测的一个有用指标。
Objective To evaluate the value of serum glycated albumin （GA）, high-sensitive reactive protein C （hsCRP）, and lipoprotein （a） in the prediction of coronary artery disease （CAD） in patients with .type 2 diabetes mellitus. Methods Levels of GA, hsCRP, glycosylated hemoglobin, and LP（a） in 69 patients with type 2 diabetes mellitus complicated with CAD （group A）, 67 patients with type 2 diabetes mellitus （group B）, and 77 normal controls （group C） were measured. Receiver operating characteristic curve （ROC curve） analysis was used to determine the optimal cutoff of identifying patients in group A from those in group B. Results There were significant differences in levels of GA, hsCRP, and LP（a） among the three groups. The area under the ROC Curve of GA was 0.607, and the optimal values of cutoff point was 18.89% （sensitivity was 73.9% and specificity was 55.2% ）. The area under the ROC curve of hsCRP was 0.746, and the optimal value of cutoff point was 5.09 mg/L （sensitivity was 50.7% and specificity was 80.1%）. The area under the ROC curve of LP（a） was 0.630, and the optimal value of cut-off point was 40 mg/L （sensitivity was 87.0% and specificity was 40.3%）. Conclusions Levels of GA, hsCRP, and LP （a） were significantly increased in type 2 diabetic patients complicated with CAD. GA can be used to predict CAD in patients with type 2 diabetes mellitus.
出处
《实用医学杂志》
CAS
北大核心
2009年第13期2161-2164,共4页
The Journal of Practical Medicine
关键词
糖尿病
2型
冠状动脉疾病
糖化白蛋白
超敏C反应蛋白
脂蛋白(a)
Diabetes mellitus,type 2
Coronary disease
Glycated albumin
High-sensitivity reactive protein C
Lipoprotein （a）
